December 23, 2019
Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, December 20, 2019, 23:30 CET — Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), […]
December 10, 2019
Vienna, Austria, and Holzgerlingen, Germany, December 10, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level […]
December 3, 2019
BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) — Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating that Epi proColon®, a […]
November 25, 2019
Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, November 25, 2019, 08:00 am CET — Curetis N.V. (the “Company” and, together with its subsidiaries, […]
November 7, 2019
Vela Diagnostics’ Sentosa® SQ HIV-1 Genotyping Assay is the first FDA De Novo designated Next Generation Sequencing (NGS) assay for detecting HIV-1 drug resistance mutations (DRMs). November […]
October 28, 2019
Vienna, Austria, and Holzgerlingen, Germany, October 28, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level […]
October 24, 2019
GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at […]
October 23, 2019
GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed […]
September 16, 2019
Holzgerlingen, Germany, and Vienna, Austria, September 16, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level […]
